---
layout: default
title: Aluminum Oxide Arsenic Trioxide Cadmium Copper Lea
parent: 僅模型預測 (L5)
nav_order: 275
evidence_level: L5
indication_count: 0
---

# Aluminum Oxide Arsenic Trioxide Cadmium Copper Lea
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Complex Multi-Component Mixture: Repurposing Evaluation Not Applicable

## One-Sentence Summary

This Evidence Pack describes a multi-component substance mixture containing 12 listed ingredients — including heavy metals (arsenic trioxide, cadmium, lead), homeopathic preparations (Mercurius Solubilis, Lycopodium clavatum), botanical materials (Plantago major), and medical device alloys (Stainless Steel 316L, titanium) — with no established pharmaceutical indication.
The TxGNN model generated **no predicted indications** for this entry, and the evidence pipeline returned **no clinical trials, no literature, and no regulatory approvals** in any jurisdiction.
This case cannot be evaluated as a drug repurposing candidate under current conditions.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None documented |
| Predicted New Indication | None (TxGNN produced no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — no predictions generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN model requires a valid DrugBank ID to locate a drug node within the knowledge graph and compute disease association scores. This entry has **no DrugBank ID**, which means the model had no anchor point from which to traverse the graph.

The listed INN is not a single active pharmaceutical ingredient but a semicolon-concatenated list of 12 heterogeneous substances:

| Substance | Category | Concern |
|-----------|----------|---------|
| Arsenic Trioxide | Heavy metal / oncology drug (if pure) | Requires isolation to evaluate |
| Cadmium | Toxic heavy metal | No therapeutic use; known carcinogen |
| Lead | Toxic heavy metal | No therapeutic use; neurotoxin |
| Mercurius Solubilis | Homeopathic mercury preparation | Not a standard pharmaceutical ingredient |
| Nickel Sulfate Hexahydrate | Metal salt | Known contact allergen; no therapeutic indication |
| Rubidium | Alkali metal | Experimental only; no approved indication |
| Aluminum Oxide | Inorganic compound | Used as excipient or abrasive, not therapeutic |
| Copper | Trace mineral | Essential nutrient; toxic in excess |
| Lycopodium Clavatum Spore | Homeopathic botanical | No pharmacological equivalence in standard databases |
| Plantago Major Whole | Herbal / homeopathic | Not mapped in DrugBank KG |
| Stainless Steel 316L | Medical device alloy | Medical implant material, not a drug |
| Titanium | Medical device material | Medical implant material, not a drug |

The co-presence of **medical device alloys** (Stainless Steel 316L, Titanium), **homeopathic preparations** (Mercurius Solubilis, Lycopodium Clavatum), and **toxic heavy metals** (cadmium, lead) in a single "drug" entry strongly suggests a **data quality issue** — this is likely a mislabeled or mis-categorized product entry rather than a coherent pharmaceutical candidate.

---

## Safety Considerations

Several components in this mixture carry significant inherent toxicity concerns, regardless of the lack of formal safety data in the system:

- **Cadmium** and **Lead** are classified as human carcinogens (IARC Group 1) with no established therapeutic window.
- **Arsenic Trioxide**, while approved as Trisenox® for acute promyelocytic leukemia (APL), requires precise dosing and carries serious risks of QT prolongation, differentiation syndrome, and hepatotoxicity. Its pharmacological benefit is inseparable from its specific purified formulation and clinical context — it cannot be evaluated as part of this mixture.
- **Nickel Sulfate** is a known sensitizer and potential carcinogen.
- **Mercurius Solubilis** contains mercury compounds; systemic mercury exposure carries neurotoxicity risk.

No formal DDI data, contraindication data, or warning text is available for this combined entry.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This entry does not represent a coherent drug repurposing candidate. The mixture combines substances from fundamentally incompatible categories — medical device materials, toxic heavy metals, and homeopathic preparations — none of which share a unified mechanism of action or a plausible combinatorial therapeutic rationale. TxGNN correctly produced no predictions because no valid knowledge graph anchor exists for this entry.

**To proceed, the following is required:**

- **Data triage**: Investigate the origin of this product entry. Determine whether it represents a real marketed product, a laboratory sample catalog entry, or a data pipeline error.
- **Disaggregate ingredients**: If any individual component (e.g., Arsenic Trioxide) is the actual substance of interest, it should be submitted as a standalone INN with its own DrugBank ID for a valid repurposing evaluation.
- **DrugBank mapping**: A DrugBank ID is a hard prerequisite for TxGNN prediction; without it, no graph-based repurposing score can be generated.
- **Regulatory clarification**: Confirm whether any regulatory body has classified this mixture as a drug, a medical device, a combination product, or a homeopathic remedy, as this determines the applicable regulatory and evidentiary framework.
- **Safety review prerequisite**: Before any repurposing pathway is considered, a formal toxicological assessment of the heavy metal components (Cd, Pb, Hg) is mandatory.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

